Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
News|Articles|September 20, 2018
Alcami to Discuss Serialization at CPhI Worldwide
Author(s)Pharmaceutical Technology Editors
The company will be presenting at CPhI Worldwide on Oct. 11, 2018.
Advertisement
Alcami announced on Aug. 15, 2018 that it will be presenting at the 2018 CPhI Worldwide event being held in Madrid, Spain on Oct. 9–11, 2018. David Molyneux, director, EU Sales and Business Development at Alcami, will discuss the challenges and complexities of serialization implementation in “Serialization–Approach to Implementation and Execution.” This Pharma Insight Briefing will be held in ICSE Theater, Hall 1 stand 1G90 from 11:50 am–12:20 pm.
Visit Alcami in Hall 10 at booth 10D50.
Source:
Advertisement
Related to this article
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Advertisement
Advertisement